Renal cell carcinoma, also known as hypernephroma or Grawitz tumor, is the most common kind of kidney cancer, accounting for almost 90% of adult cases. Renal cell carcinoma (RCC), which makes up more than 3% of all adult malignancies and includes a variety of histological subtypes. It is an older age group tumor with a roughly 2:1 male to female ratio that is most frequently observed between the ages of 50 and 70. Prognosis 90% - 2 year survival (with spread) and Poor prognosis with Loss of genetic material on Chr11q,16q and Gain of Chr1q. There are currently several different biomarkers available that could assist direct the tailored treatment of kidney cancer patients. Renal tumors, commonly referred to as kidney tumors, are abnormal growths that start in one or both kidneys' renal tissues. The many serum, imaging, and immunohistological biomarkers that are now used in clinical practice will be covered in this review, along with potential future paths for the creation of new RCC biomarkers.